Financial Counselors Inc increased its stake in Amgen Inc (AMGN) by 29.19% based on its latest 2017Q4 regulatory filing with the SEC. Financial Counselors Inc bought 18,743 shares as the company’s stock declined 2.99% with the market. The institutional investor held 82,957 shares of the biological products (no diagnostic substances) company at the end of 2017Q4, valued at $14.43 million, up from 64,214 at the end of the previous reported quarter. Financial Counselors Inc who had been investing in Amgen Inc for a number of months, seems to be bullish on the $119.30B market cap company. The stock increased 1.51% or $2.66 during the last trading session, reaching $179.13. About 1.85M shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 3.78% since May 22, 2017 and is uptrending. It has underperformed by 7.77% the S&P500.
Parametric Portfolio Associates Llc decreased its stake in Aes Corp/The (AES) by 9.43% based on its latest 2017Q4 regulatory filing with the SEC. Parametric Portfolio Associates Llc sold 274,786 shares as the company’s stock rose 2.24% while stock markets declined. The institutional investor held 2.64M shares of the central company at the end of 2017Q4, valued at $28.58M, down from 2.91M at the end of the previous reported quarter. Parametric Portfolio Associates Llc who had been investing in Aes Corp/The for a number of months, seems to be less bullish one the $8.07B market cap company. The stock increased 1.20% or $0.145 during the last trading session, reaching $12.205. About 3.41 million shares traded. The AES Corporation (NYSE:AES) has declined 1.62% since May 22, 2017 and is downtrending. It has underperformed by 13.17% the S&P500.
Financial Counselors Inc, which manages about $2.18B US Long portfolio, decreased its stake in Clorox Company (NYSE:CLX) by 2,221 shares to 10,297 shares, valued at $1.53M in 2017Q4, according to the filing. It also reduced its holding in Genuine Parts Co (NYSE:GPC) by 3,963 shares in the quarter, leaving it with 28,306 shares, and cut its stake in Exxon Mobil Corp (NYSE:XOM).
Since December 12, 2017, it had 0 buys, and 6 selling transactions for $1.64 million activity.
More notable recent Amgen Inc. (NASDAQ:AMGN) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict” on May 22, 2018, also Seekingalpha.com with their article: “Expanded label for Amgen’s Repatha approved in Europe” published on May 16, 2018, 247Wallst.com published: “Amgen Wins Another FDA Approval” on May 22, 2018. More interesting news about Amgen Inc. (NASDAQ:AMGN) were released by: Seekingalpha.com and their article: “Amgen’s Dim Sales Outlook Looms Over Buybacks” published on April 26, 2018 as well as 247Wallst.com‘s news article titled: “Amgen’s Novel Migraine Treatment Gets Key Approval” with publication date: May 18, 2018.
Among 25 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 14 Hold. Therefore 44% are positive. Amgen Inc. had 89 analyst reports since August 3, 2015 according to SRatingsIntel. Oppenheimer maintained Amgen Inc. (NASDAQ:AMGN) rating on Friday, July 28. Oppenheimer has “Buy” rating and $20300 target. The rating was maintained by Bernstein with “Hold” on Wednesday, June 7. RBC Capital Markets maintained the stock with “Hold” rating in Monday, January 22 report. The rating was maintained by BMO Capital Markets with “Market Perform” on Thursday, October 26. The rating was maintained by Oppenheimer with “Buy” on Wednesday, July 12. The firm earned “Overweight” rating on Thursday, October 26 by Morgan Stanley. Piper Jaffray maintained it with “Buy” rating and $194.0 target in Thursday, January 18 report. The rating was maintained by Mizuho with “Buy” on Friday, July 14. Oppenheimer maintained Amgen Inc. (NASDAQ:AMGN) on Tuesday, August 29 with “Buy” rating. The rating was maintained by Cowen & Co on Thursday, July 20 with “Buy”.
Investors sentiment increased to 1.22 in Q4 2017. Its up 0.23, from 0.99 in 2017Q3. It increased, as 73 investors sold AMGN shares while 458 reduced holdings. 122 funds opened positions while 527 raised stakes. 551.71 million shares or 0.60% less from 555.05 million shares in 2017Q3 were reported. Endurance Wealth Mgmt holds 0.96% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 34,247 shares. Deutsche National Bank Ag accumulated 4.26 million shares. Lord Abbett And Com Ltd Liability Corporation reported 0.15% in Amgen Inc. (NASDAQ:AMGN). Goldman Sachs Gp invested in 0.32% or 7.64 million shares. Boston And Mgmt reported 1,180 shares or 0.1% of all its holdings. Affinity Invest Advisors Llc holds 1.63% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 82,440 shares. Sva Plumb Wealth Lc reported 0.4% stake. Gateway Advisers Limited Liability Co invested in 0.61% or 410,878 shares. Highland Cap Mngmt Ltd reported 27,064 shares. Founders Securities Ltd invested 0.21% in Amgen Inc. (NASDAQ:AMGN). E&G LP invested in 0.18% or 2,500 shares. Hallmark Cap Mngmt reported 2.12% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Zwj Investment Counsel invested in 0.1% or 7,197 shares. Moreover, Oarsman Cap has 0.51% invested in Amgen Inc. (NASDAQ:AMGN). King Luther Cap Mgmt Corp holds 0.86% or 601,459 shares.
Parametric Portfolio Associates Llc, which manages about $100.26 billion US Long portfolio, upped its stake in Enel Spa (ENLAY) by 463,597 shares to 4.55 million shares, valued at $27.81M in 2017Q4, according to the filing. It also increased its holding in Dynegy Inc New (NYSE:DYN) by 114,579 shares in the quarter, for a total of 734,763 shares, and has risen its stake in American Airlines Group Inc (NASDAQ:AAL).
Analysts await The AES Corporation (NYSE:AES) to report earnings on August, 14. They expect $0.29 earnings per share, up 16.00% or $0.04 from last year’s $0.25 per share. AES’s profit will be $191.80 million for 10.52 P/E if the $0.29 EPS becomes a reality. After $0.28 actual earnings per share reported by The AES Corporation for the previous quarter, Wall Street now forecasts 3.57% EPS growth.